REUTERS/Carlos Osorio

Bayer, Meda sue Apotex over proposed Astepro Allergy generic

The corporate and legislation agency names proven above are generated routinely based mostly on the textual content of the article. We’re bettering this characteristic as we proceed to check and develop in beta. We welcome suggestions, which you’ll be able to present utilizing the suggestions tab on the fitting of the web page.

(Reuters) – Bayer Healthcare and Viatris’ Meda Prescription drugs have sued Canadian generic drugmaker Apotex in Delaware federal court docket, alleging its proposed generic model of Astepro Allergy nasal spray infringes its patents.

The U.S. Meals and Drug Administration approved Bayer’s Astepro Allergy for nonprescription use in June. Bayer has stated it’s the first over-the-counter, steroid-free antihistamine allergy spray within the U.S.

The Thursday complaint requested the usDistrict Court docket for the District of Delaware to delay FDA approval of Apotex’s generic drug till the final Astepro patent expires in 2028, and to dam Apotex from making it earlier than then. The lawsuit additionally initiates a 30-month keep of the approval course of below the Hatch-Waxman Act.

Meda acquired FDA approval for the prescription model of Astepro in 2009. Bayer spokesperson Chris Loder stated in an announcement that the corporate licenses the patents from Meda and has the fitting to implement them in opposition to alleged infringers.

Apotex did not instantly reply to a request for remark. Viatris additionally did not instantly reply, nor did Bayer’s attorneys Dov Grossman of Williams & Connolly and Jack Blumenfeld of Morris Nichols Arsht & Tunnell, or Meda’s attorneys Brandon White of Perkins Coie and Jennifer Ward of Wilson Sonsini Goodrich & Rosati.

Bayer and Meda’s swimsuit follows Apotex’s submitting of an Abbreviated New Drug Utility for FDA approval of its generic drug. An ANDA asserts that the related drug patents are invalid or wouldn’t be infringed by the generic drug, and opens the applicant to infringement claims from the patent proprietor.

The grievance says Apotex advised the FDA that the related components of the patents have been invalid.

The case is Bayer Healthcare LLC v. Apotex Inc, U.S. District Court docket for the District of Delaware, No. 1:21-cv-01429.

For Bayer: Dov Grossman of Williams & Connolly and Jack Blumenfeld of Morris Nichols Arsht & Tunnell

For Meda: Brandon White of Perkins Coie and Jennifer Ward of Wilson Sonsini Goodrich & Rosati

Blake Brittain

Blake Brittain reviews on mental property legislation, together with patents, emblems, copyrights and commerce secrets and techniques. Attain him at [email protected]